J
Jun Liang
Researcher at Qingdao University
Publications - 11
Citations - 980
Jun Liang is an academic researcher from Qingdao University. The author has contributed to research in topics: Bevacizumab & Capecitabine. The author has an hindex of 7, co-authored 11 publications receiving 745 citations.
Papers
More filters
Journal ArticleDOI
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Jin Li,Shukui Qin,Jianming Xu,Jianping Xiong,Changping Wu,Yuxian Bai,Wei Liu,Jiandong Tong,Yunpeng Liu,Rui-Hua Xu,Zhehai Wang,Qiong Wang,Xuenong Ouyang,Yan Yang,Yi Ba,Jun Liang,Xiaoyan Lin,Deyun Luo,Rongsheng Zheng,Xin Wang,Guoping Sun,Liwei Wang,Leizhen Zheng,Hong Guo,Jingbo Wu,Nong Xu,Jianwei Yang,Hong-gang Zhang,Ying Cheng,Ningju Wang,Lei Chen,Zhining Fan,Piaoyang Sun,Hao Yu +33 more
TL;DR: These data show that apatinib treatment significantly improved OS and PFS with an acceptable safety profile in patients with advanced gastric cancer refractory to two or more lines of prior chemotherapy.
Journal ArticleDOI
Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial
Zhong Zhen Guan,Jianming Xu,Rong Cheng Luo,Feng Yi Feng,Li Wei Wang,Lin Shen,Shi Ying Yu,Yi Ba,Jun Liang,Dong Wang,Shu Kui Qin,Jie Jun Wang,Jing He,Chuan Qi,Rui-Hua Xu +14 more
TL;DR: Bevacizumab plus mIFL is effective and well tolerated as first-line treatment for Chinese patients with mCRC and clinical benefit and safety profiles were consistent with those observed in pivotal phase III trials with mainly Caucasian patients.
Journal ArticleDOI
Efficacy and Safety of the FOLFOX4 Regimen Versus Doxorubicin in Chinese Patients With Advanced Hepatocellular Carcinoma: A Subgroup Analysis of the EACH Study
Shukui Qin,Ying Cheng,Jun Liang,Lin Shen,Yuxian Bai,Jianfeng Li,Jia Fan,Lijian Liang,Yaqi Zhang,Gang Wu,Kun Ming Rau,Tsai Shen Yang,Zhixiang Jian,Houjie Liang,Yan Sun +14 more
TL;DR: For Chinese HCC patients enrolled in the EACH study, FOLFOX4 significantly improved the RR and DCR and prolonged survival compared with doxorubicin, and may play an important role in the treatment of Chinese patients with advanced HCC.
Journal ArticleDOI
Icaritin‐induced immunomodulatory efficacy in advanced hepatitis B virus‐related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival
Shukui Qin,Qing Li,Jianming Xu,Jun Liang,Ying Cheng,Ying Fan,Jun Jiang,Hao Ye,Huimin Tao,Lian Li,Limin Zheng,Zhaohui Wei,Shu Li,Meng Kun,Bin Ye,Yan Sun +15 more
TL;DR: Icaritin is a small molecule that has displayed anticancer activities through IL-6/JAK/STAT3 pathways in tumor cells and immune cells including CD8+ T cells, MDSCs, neutrophils, and macrophages.
Journal ArticleDOI
Expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2014 version)
Yan Sun,Zhongzhen Guan,Meilin Liao,Xin Yu,Changli Wang,Jie Wang,Xiaohui Niu,Yuankai Shi,Xiuyi Zhi,Yunpeng Liu,Mengzhong Liu,Yiping Zhang,Yue Yang,Jingnan Shen,Gongyan Chen,Qinghua Zhou,Caicun Zhou,Qisen Guo,Lili Tang,Jianchun Duan,Jun Liang,Yingjian Zhang,Ying Cheng +22 more
TL;DR: Expert Consensus on the Diagnosis and Treatment of Bone Metastasis in Lung Cancer (2014 version)